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 A quick reference guide for healthcare professionals. 
 Information for people who want to quit smoking and their carers 
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 Details of all the evidence that was looked at and other background 
information. 
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1 Guidance 
1.1 Varenicline is recommended within its licensed indications as an 
option for smokers who have expressed a desire to quit smoking. 
1.2 Varenicline should normally be prescribed only as part of a 
programme of behavioural support.  
2 The technology 
2.1 Varenicline (Champix, Pfizer) has marketing authorisation for 
smoking cessation in adults. The summary of product 
characteristics (SPC) states that smokers should set a date to stop 
smoking and treatment with varenicline should start 1 to 2 weeks 
before this date and that smoking cessation therapies are more 
likely to succeed for patients who are provided with additional 
advice and support.  
2.2 Varenicline binds with high affinity and selectivity at the 
α4β2 neuronal nicotinic acetylcholine receptor, where it acts as a 
partial agonist. Its binding both alleviates symptoms of craving and 
withdrawal, and reduces the rewarding and reinforcing effects of 
smoking by preventing nicotine binding to α4β2 receptors. 
2.3 Varenicline may be associated with nausea and other 
gastrointestinal disorders such as vomiting. For full details of side 
effects and contraindications, see the SPC. 
2.4 Varenicline is available in 0.5-mg and 1-mg film-coated tablets. The 
cost is £54.60 for a 56-blister pack of 0.5- or 1-mg tablets (‘British 
national formulary’ [BNF] edition 53). A 12-week course of 
treatment costs about £163.80. The SPC specifies the option of an 
additional 12 weeks of treatment and the consideration of dose 
tapering. Costs may vary in different settings because of negotiated 
procurement discounts. 
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3 The manufacturer’s submission 
The Appraisal Committee (appendix A) considered evidence 
submitted by the manufacturer of varenicline and a review of this 
submission by the Evidence Review Group (ERG: appendix B). 
3.1 The manufacturer’s primary analysis compared the standard 12-
week course of varenicline with bupropion and nicotine 
replacement therapy (NRT). The manufacturer identified four 
randomised controlled trials (RCTs). Two were three-arm trials that 
compared varenicline, bupropion and placebo (n = 1483 and 1413). 
Another trial compared maintenance treatment (24-week course of 
varenicline) with placebo (n = 2416). The manufacturer also 
presented data from an open-label trial (n = 957) that compared 
varenicline with NRT. 
3.2 The two trials that compared varenicline and bupropion showed 
that the continuous quit rate for weeks 9–12 was statistically 
significantly greater for varenicline: odds ratio (OR) 1.93 (95% CI 
1.40 to 2.68) and OR 1.90 (95% CI 1.40 to 2.68), respectively. Both 
trials also showed that the continuous quit rate for varenicline was 
statistically significantly greater than for placebo: OR 3.85 (95% CI 
2.70 to 5.50) and OR 3.85 (95% CI 2.69 to 5.50), respectively. For 
the longer time horizon of weeks 9–52, the ORs for varenicline 
compared with bupropion, respectively for the two trials, were 1.46 
(95% CI 0.99 to 2.17) and 1.77 (95% CI 1.19 to 2.63). The 
maintenance trial that compared 24-week varenicline with placebo 
showed that the continuous quit rate was statistically significantly 
greater with varenicline than with placebo: weeks 13–24 OR 2.47 
(95% CI 1.95 to 3.15); weeks 13–52 OR 1.35 (95% CI 1.07 to 
1.70). The results of the open-label trial were marked confidential 
by the manufacturer. 
3.3 The manufacturer also submitted a meta-analysis of 70 NRT trials, 
12 bupropion trials and 4 varenicline trials against control/placebo. 
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The meta-analysis indirectly compared the efficacy of the 
treatments based on relative treatment effects. This indirect 
comparison showed that at 12 months varenicline was superior to 
NRT (OR 1.66 [CI 1.17 to 2.36]) and bupropion (OR 1.58 [95% CI 
1.22 – 2.05]). Varenicline was also superior at 3 months to both 
NRT (OR 1.78 [95% CI 1.23 to 2.57]) and bupropion (OR 1.61 
[95% CI 1.17 to 2.22]). 
3.4 The manufacturer presented a cost-effectiveness analysis based 
on a Markov model. It assumes an individual makes a single quit 
attempt at the beginning of the model. The individual is followed 
from this initial quit attempt to various health states and potential 
comorbidities including lung cancer, asthma exacerbations, chronic 
obstructive pulmonary disease, stroke and cardiovascular disease. 
The probabilities of relapsing and developing comorbidities are 
assumed to decrease over time from smoking cessation. The 
efficacy rates for the treatments are calculated from the odds ratios 
derived from the results of the pooled direct clinical trials and the 
indirect comparison. The probabilities associated with relapse are 
derived from relative risks reported in US-based long-term 
longitudinal and cohort studies into smoking and abstinence. The 
costs and utilities are derived from several published sources. 
Some health-related utility estimates are based on US data, 
including baseline health-related utilities. 
3.5 The base-case analysis showed that over a lifetime horizon 
varenicline dominated bupropion and NRT – that is, it was cheaper 
and more effective. Variation of the time horizon used in the 
analysis showed that, at 20 years and over, varenicline maintained 
its dominating position. Sensitivity analyses included altering 
baseline health-related utilities and costs of NRT, and the use of 
efficacy rates from the direct open-label trial that compared 
varenicline with NRT. Over a lifetime horizon varenicline dominated 
NRT and bupropion in all sensitivity analysis. 
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3.6 The ERG noted that the inclusion/exclusion criteria of the meta-
analysis in the manufacturer’s submission differed from existing 
analyses by the Cochrane collaboration and considered that they 
could overestimate the efficacy of varenicline. The ERG also 
conducted its own meta-analysis and indirect comparison which 
suggested that the odds ratio for varenicline in comparison with 
NRT was lower than in the manufacturer’s model: OR 1.54 (95% CI 
1.10 to 2.16). 
3.7 The ERG noted that the assumptions included in the model could 
make external validity questionable. For example, it considered that 
the assumption of a single quit attempt was a limitation that did not 
allow consideration of the impact of subsequent quit attempts on 
costs, morbidity or mortality. In addition, the extrapolation of data 
on 1-year quit rates to a lifetime is associated with considerable 
uncertainty surrounding the long-term relapse or abstinence 
experience of the model cohort. The ERG noted that the use of 
indirect comparison in the base case was inappropriate given the 
availability of direct trial evidence. The ERG further identified some 
computational errors in the calculation of transition probabilities and 
population calculations. The ERG commented that the method 
used to convert odds ratios to efficacy rates was not validated and 
a model constructed around odds ratios would have been more 
appropriate. The ERG compared the number of life years gained in 
the model with the results of two published analyses and found no 
substantial differences. 
3.8 Full details of all the evidence are in the manufacturer’s submission 
and the ERG report, which are available from 
www.nice.org.uk/TA123 
4 Consideration of the evidence 
4.1 The Appraisal Committee reviewed the data available on the 
clinical and cost effectiveness of varenicline, having considered 
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evidence on smoking cessation and the value placed on the 
benefits of varenicline by people who smoke tobacco products and 
want to quit, those who represent them, and clinical specialists. It 
was also mindful of the need to take account of the effective use of 
NHS resources. 
4.2 The Committee considered the clinical effectiveness evidence 
presented by the manufacturer. It concluded that the evidence from 
the direct trials and the systematic reviews carried out by the 
manufacturer and ERG demonstrated that varenicline was superior 
to NRT and bupropion in achieving continuous abstinence. The 
Committee heard from the clinical specialists and patient experts 
that the success rates with varenicline made it a useful addition to 
the variety of interventions available in smoking cessation, 
particularly because many smokers need to make multiple quit 
attempts. The availability of an additional treatment choice was 
mentioned by clinical specialists and patient experts as beneficial to 
those having difficulty maintaining abstinence and avoiding relapse 
because it enabled them to have more control. 
4.3 The Committee considered the evidence on the cost effectiveness 
of varenicline submitted by the manufacturer. The Committee noted 
the comments of the ERG that the submission was not transparent 
and possessed limited external validity. The model included an 
extrapolation of 1-year clinical data to a lifetime horizon and 
included an assumption of a single quit attempt. The Committee 
also noted the computational errors identified by the ERG, and 
noted that the ERG had expressed concerns about a number of 
other assumptions in the model, in particular the use of US data for 
baseline risk and the use of all-cause morbidity instead of other-
cause morbidity. Nevertheless, the Committee considered that 
these concerns were not sufficient to undermine the inference that 
the use of varenicline in smoking cessation was likely to be a cost-
effective use of NHS resources. 
 NICE technology appraisal guidance 123   6
   
4.4 The Committee heard from clinical specialists about the importance 
of counselling and support in smoking cessation to reinforce the 
commitment required to quit smoking. It noted that varenicline had 
been provided alongside counselling and support in the clinical 
trials. However, the Committee also heard from the clinical 
specialists that counselling and support are not always used by 
people aiming to stop smoking and that pharmacotherapies can be 
effective in the absence of such programmes. The Committee 
concluded that varenicline should normally be provided in 
conjunction with counselling and support, but that if such support is 
refused or is not available, this should not preclude treatment with 
varenicline. 
5 Implementation 
5.1 The Healthcare Commission assesses the performance of NHS 
organisations in meeting core and developmental standards set by 
the Department of Health in ‘Standards for better health’ issued in 
July 2004. The Secretary of State has directed that the NHS 
provides funding and resources for medicines and treatments that 
have been recommended by NICE technology appraisals normally 
within 3 months from the date that NICE publishes the guidance. 
Core standard C5 states that healthcare organisations should 
ensure they conform to NICE technology appraisals. 
5.2 'Healthcare Standards for Wales’ was issued by the Welsh 
Assembly Government in May 2005 and provides a framework both 
for self-assessment by healthcare organisations and for external 
review and investigation by Healthcare Inspectorate Wales. 
Standard 12a requires healthcare organisations to ensure that 
patients and service users are provided with effective treatment 
and care that conforms to NICE technology appraisal guidance. 
The Assembly Minister for Health and Social Services issued a 
Direction in October 2003 which requires Local Health Boards and 
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NHS Trusts to make funding available to enable the implementation 
of NICE technology appraisal guidance, normally within 3 months.  
5.3 NICE has developed tools to help organisations implement this 
guidance (listed below). These are available on our website 
(www.nice.org.uk/TA123).  
 Local costing template incorporating a costing report to estimate 
the savings and costs associated with implementation. 
 Audit criteria to monitor local practice. 
6 Recommendation for further research 
6.1 The Committee recommends that research is conducted into the 
long-term effectiveness of smoking cessation interventions with 
particular reference to relapse rates after completion of treatment.  
7 Related NICE guidance 
7.1 NICE has issued the following related technology appraisal 
guidance and clinical guidelines. 
 Guidance on the use of nicotine replacement therapy (NRT) and 
bupropion for smoking cessation. NICE technology appraisal 
guidance 39 (2002). Available from: www.nice.org.uk/TA039 
 Brief interventions and referral for smoking cessation in primary 
care and other settings. NICE public health intervention 
guidance 1 (2006). Available from: www.nice.org.uk/PHI001 
 Workplace health promotion: how to help employees to stop 
smoking. NICE public health intervention guidance 5 (2007). 
Available from: www.nice.org.uk/PHI005 
7.2 NICE is developing the following guidance (details available from 
www.nice.org.uk) 
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 Smoking cessation services, including the use of 
pharmacotherapies, in primary care, pharmacies, local 
authorities and workplaces, with particular reference to manual 
working groups, pregnant women who smoke and hard to reach 
communities. NICE public health programme guidance 
(publication expected November 2007). 
8 Review of guidance 
8.1 The review date for a technology appraisal refers to the month and 
year in which the Guidance Executive will consider whether the 
technology should be reviewed. This decision will be taken in the 
light of information gathered by the Institute, and in consultation 
with consultees and commentators. 
8.2 The guidance on this technology will be considered for review in 
May 2010. 
 
Andrew Dillon 
Chief Executive 
July 2007 
 NICE technology appraisal guidance 123   9
   
Appendix A. Appraisal Committee members, public 
health programme representative and NICE project 
team 
A. Appraisal Committee members 
The Appraisal Committee is a standing advisory committee of the Institute. Its 
members are appointed for a 3-year term. A list of the Committee members 
who took part in the discussions for this appraisal appears below. The 
Appraisal Committee meets three times a month except in December, when 
there are no meetings. The Committee membership is split into three 
branches, with a chair and vice chair. Each branch considers its own list of 
technologies, and ongoing topics are not moved between the branches.  
Committee members are asked to declare any interests in the technology to 
be appraised. If it is considered there is a conflict of interest, the member is 
excluded from participating further in that appraisal.  
The minutes of each Appraisal Committee meeting, which include the names 
of the members who attended and their declarations of interests, are posted 
on the NICE website. 
Professor David Barnett  
Professor of Clinical Pharmacology, University of Leicester 
Dr David W Black 
Director of Public Health, Derbyshire County PCT 
Mr Brian Buckley 
Chairman, Incontact 
Dr Carol Campbell 
Senior Lecturer, University of Teesside 
Professor Mike Campbell 
Professor of Medical Statistics, University of Sheffield 
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Ms Jude Cohen 
Manager of Resources and Administration, Council for Psychotherapy (UKCP) 
Dr Christine Davey 
Senior Researcher, North Yorkshire Alliance R & D Unit 
Dr Mike Davies 
Consultant Physician, Manchester Royal Infirmary 
Mr Richard Devereaux-Phillips 
Public Affairs Manager, Medtronic 
Dr Rachel A Elliott 
Clinical Senior Lecturer, University of Manchester 
Mrs Eleanor Grey 
Lay member 
Dr Catherine Jackson 
Clinical Lecturer in Primary Care Medicine, Alyth Health Centre 
Dr Peter Jackson 
Clinical Pharmacologist, University of Sheffield 
Ms Rachel Lewis 
Practice Development Facilitator, Manchester PCT 
Professor Jonathan Michaels 
Professor of Vascular Surgery, University of Sheffield 
Dr Eugene Milne 
Deputy Medical Director, North East Strategic Health Authority 
Dr Richard Alexander Nakielny 
Consultant Radiologist, Royal Hallamshire Hospital, Sheffield 
Dr Katherine Payne 
Health Economics Research Fellow, University of Manchester 
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Professor Andrew Stevens (Chair)  
Professor of Public Health, University of Birmingham  
Dr Cathryn Thomas 
Senior Lecturer, University of Birmingham 
B Public health programme representative 
The following individual, representing the programme development group 
responsible for developing the Institute’s public health programme guidance 
related to this topic, attended the meeting to observe and to contribute as an 
adviser to the Committee. 
 Dr Paul Aveyard, Senior Lecturer, Department of Primary 
Care and General Practice, University of Birmingham 
 
C. NICE project team 
Each technology appraisal is assigned to a team consisting of one or more 
health technology analysts (who act as technical leads for the appraisal), a 
technical adviser and a project manager.  
Prashanth Kandaswamy 
Technical Lead 
Louise Longworth 
Technical Adviser 
Chris Feinmann 
Project Manager 
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Appendix B. Sources of evidence considered by the 
Committee 
A The evidence review group (ERG) report for this appraisal was prepared 
by the School of Health and Related Research (ScHARR): 
D Hind, P Tappenden, J Peters, K Kenjegalieva. Varenicline for 
smoking cessation: a single technology appraisal (March 2007). 
B The following organisations accepted the invitation to participate in this 
appraisal. They were invited to comment on the draft scope. 
Organisations listed in I were also invited to make written submissions. 
Organisations listed in II gave their expert views on varenicline by 
providing a written statement to the Committee. Organisations listed in I 
and II have the opportunity to appeal against the final appraisal 
determination. 
I Manufacturer/sponsor: 
 Pfizer Ltd 
II Professional/specialist and patient/carer groups: 
 Action Heart 
 British Heart Foundation 
 Burnley, Pendle and Rossendale PCT 
 Cancer Research UK 
 General Practice Airways Group 
 Macmillan Cancer Relief 
 National Lung Cancer Forum for Nurses 
 Primary Care Cardiovascular Society 
 Roy Castle Lung Cancer Foundation 
 Royal College of Nursing 
 Royal College of Physicians 
 Welsh Assembly Government 
III Commentator organisations (did not provide written evidence and 
without the right of appeal): 
 British National Formulary 
 British Society for Cardiovascular Research 
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 Department of Health, Social Services and Public Safety for 
Northern Ireland 
 GlaxoSmithKline (Bupropion) 
 GlaxoSmithKline Consumer Healthcare (Nicotine) 
 Medicines and Healthcare Products Regulatory Agency 
(MHRA) 
 National Coordinating Centre for Health Technology 
Assessment 
 NHS Quality Improvement Scotland 
 School of Health and Related Research (ScHARR), University 
of Sheffield 
C The following individuals were selected from clinical specialist and 
patient advocate nominations from the professional/specialist and 
patient/carer groups. They gave their expert personal view on varenicline 
by providing written evidence to the Committee. 
 Dr Katherine Willmer, Consultant Cardiologist, nominated by 
the British Cardiovascular Society – clinical specialist 
 Mrs Christine Owens, Head of Tobacco Control of and 
nominated by the Roy Castle Lung Cancer Foundation – 
patient expert 
 Mr David Geldard, President, Heart Care Partnership (UK), 
nominated by the British Cardiovascular Society – patient 
expert 
 
 
